Drug intelligence / Profile preview

GSP15003

Development stage: Unknown
Lead developer: Green Sky Labs
Administration: Subcutaneous

Overview

GSP15003 is a pharmaceutical drug candidate developed by Green Sky Labs. It is being evaluated in Phase 3 clinical development for the treatment of Post-Traumatic Stress Disorder (PTSD). While Green Sky Labs is known for its focus on cannabinoid-based therapies and medical cannabis extraction technologies, specific details regarding the chemical structure, modality, and molecular targets of GSP15003 have not been publicly disclosed.

Beyond the preview

Go deeper on GSP15003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSP15003.

Explore the full profile